Osteoarthritis Patient-Focused Drug Development
The Arthritis Foundation hosted an Osteoarthritis (OA) Patient-Focused Drug Development (PFDD) meeting in the Washington, D.C. area on March 8, 2017. This meeting provided the U.S. Food and Drug Administration (FDA), drug developers, health care providers, academic researchers, and other stakeholders an opportunity to hear directly from patients, patient advocates and caretakers about the signs and symptoms that matter most to them. OA patients shared just how much this disease impacts their lives, as well as the gaps in treatment and how treatment helps them. The meeting was a tremendous step in the right direction in bringing new treatments to market.
FDA Discusses the Importance of PFDD Meetings
Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research at the FDA, talk about the importance of PFDD meetings and how they are impactful for both participants and the FDA.
Osteoarthritis Patient-Focused Drug Development Meeting
Watch the full OA PFDD meeting here.
In an effort to collect information from OA patients about their experiences with OA, we hosted a webinar for OA patients on January 31, 2017. Patients responded to questions about their experiences with OA including treatments and asked a rheumatologist and orthopedic surgeon questions about their disease and the future of treatments. Watch the webinar below to learn more.
Advancing Osteoarthritis Treatment Webinar
In addition to the webinar, we hosted five focus groups around the country to collect critical information about the impact of OA. They were held in Indianapolis, Indiana; West Palm Beach, Florida; New York City, New York; Phoenix, Arizona; and San Leandro, California. In each of these conversations we collected insights about the true impact of this debilitating disease, what patients’ experiences have been with the treatments currently available, and what the OA community hopes for in treatments of the future.